Multiplan CORP 8-K filings

Claritev Corporation announced the passing of Board Director John Prince on July 6, 2026, who was a member of the Audit Committee.

Claritev Corporation issues a statement clarifying its cooperation with a DOJ antitrust investigation into health insurance, following recent media reports.

Claritev Corporation announced its first quarter 2026 financial results, reporting revenue growth and an increase in Adjusted EBITDA, while also detailing a net loss and increased cash used in operations.

Claritev Corporation stockholders approved the election of four directors and an increase of 2.375 million shares for the 2020 Omnibus Incentive Plan.

Claritev Corporation's 2026 Investor Day presentation outlines a strategic roadmap for sustained growth, digital transformation, and AI integration, projecting significant revenue and EBITDA increases by 2030.

Claritev Corporation announced robust fourth quarter and full-year 2025 financial results, including a return to revenue growth and improved profitability, alongside the approval of a new $75 million share repurchase program.

Claritev Corporation outlined its strategic Vision 2030, focusing on growth, market expansion, and technology investment at the J.P. Morgan 44th Annual Healthcare Conference.

Claritev Corporation announced that Dale White, former CEO and Executive Chair, will conclude his strategic advisor role effective December 31, 2025, while remaining a board director.

Claritev Corporation's selling stockholders, affiliates of Hellman & Friedman, completed a secondary public offering of 1.5 million Class A common shares at $51.50 per share, with the company receiving no proceeds.

Claritev Corporation announced improved third-quarter 2025 financial results, including 6.7% revenue growth and a significantly narrowed net loss, leading to an increase in its full-year revenue guidance.

Claritev Corporation announced the successful renewal of contracts with its ten largest clients, representing a significant portion of its 2024 revenues.

Claritev Corporation announced the appointment of Brock Albinson as its Senior Vice President and Chief Accounting Officer, effective September 29, 2025.

Claritev Corporation announced a comprehensive strategic vision, digital transformation, and raised its full-year 2025 financial guidance, signaling accelerated growth and market expansion.

Claritev Corporation announced significantly improved second-quarter 2025 financial results, returning to revenue growth and updating its full-year guidance positively.

Claritev Corporation announced its Q1 2025 financial results, featuring a revenue decrease, reduced net loss, and reaffirmed full-year guidance as it progresses through its 'Year of The Turn' transformation.

Claritev Corporation's stockholders approved an amendment to the 2020 Omnibus Incentive Plan, increasing the share reserve by 1,750,000 shares at the Annual Meeting.

Claritev Corporation updates compensation and severance terms for its CEO, CFO, and other executives, including provisions related to change in control scenarios and equity grants.

Claritev Corporation outlines its strategic vision, transformation plan, and financial guidance for 2025 during an investor roundtable presentation.

Claritev Corporation, formerly MultiPlan, announces its Q4 and full year 2024 financial results, along with initial guidance for full year 2025, highlighting revenue, net loss, and adjusted EBITDA figures.

Claritev Corporation announces a multi-year transformation program aimed at modernizing operations, driving cost efficiencies, and positioning the company for future growth as part of its Vision 2030 plan.

MultiPlan Corporation announces a corporate rebrand to Claritev, signaling a new era focused on innovation and transparency in the healthcare ecosystem.

MultiPlan Corporation successfully completed a debt refinancing transaction, including the exchange of existing notes for new debt instruments and the establishment of new senior secured credit facilities.

MultiPlan successfully completed exchange offers for its outstanding notes and term loans, achieving over 99% participation from existing noteholders and lenders.

MultiPlan Corporation's Executive Chair, Dale White, has stepped down from his role and employment, transitioning to a Strategic Advisor position while remaining on the Board of Directors.

MultiPlan has announced a comprehensive refinancing agreement with key noteholders and lenders, extending debt maturities and supporting its Vision 2030 transformation plan.

MultiPlan's Q3 2024 results included a substantial net loss due to a goodwill impairment, while revenues and adjusted EBITDA were in line with the low end of guidance, leading to a tightening of full-year revenue guidance and a slight decrease to the top end of adjusted EBITDA guidance.

MultiPlan Corporation has completed a 1-for-40 reverse stock split of its Class A common stock, effective September 20, 2024, to increase its per-share trading price and meet NYSE listing requirements.

MultiPlan Corporation is in discussions with debt holders to optimize its capital structure and facilitate its transition into a data and technology-focused healthcare company.

Glenn R. August has resigned from the MultiPlan Corporation Board of Directors, effective immediately, with no indication of disagreement with the company.

MultiPlan Corporation will implement a 1-for-40 reverse stock split of its Class A common stock, effective September 20, 2024, to increase its per share trading price and meet NYSE listing requirements.